Epithelial Ovarian Cancer with Endometriosis is not Associated with Menopausal Status: a Co-Association Study at Prapokklao Hospital

Supanee Muangtan, Wineeya Suknikhom*, Panya Sananpanichkul

Abstract

Objective: To determine any association between the menopausal status and epithelial ovarian cancer coexisting with endometriosis (EOC-E). In addition, the prevalence and possible risk factors were assessed. Methods: Medical records of 172 women with epithelial ovarian cancer between January 2011 and December 2016 at Prapokklao Hospital were reviewed and divided into two groups: EOC-E defined as the case group and without endometriosis (EOC-NE) as the control group. Results: The proportion of EOC-E was 18% (31/172). There were no significant differences between the two groups in baseline clinical characteristics and presenting symptoms except for history of smoking and abnormal uterine bleeding found more often in EOC-E cases. Most EOC-E were of clear cell histological type followed by endometrioid and serous types (35.5, 25.8 and 22.6 %; respectively). The clear cell type was 8 times more likely in the EOC-E than in the EOC-NE (OR 8.0, 95% CI 2.97-21.89, p-value <0.001) group. Nulliparity and smoking increased risk of EOC-E 2 and 7 times, respectively (OR 2.3, 95%CI 1.03-5.00, p-value 0.041 and OR 7.4, 95%CI 1.18-46.63, p-value 0.032). Conclusions: EOC-E are relatively common. Abnormal uterine bleeding is the only significant presenting symptom in the EOC-E as compared with the EOC-NE group. Endometriosis was a predictive factor for clear cell and endometrioid type I EOC. Menopausal status and age were not associated with a presentation of endometriosis with EOC.

Keywords: Epithelial ovarian cancer- endometriosis- prevalence- risk factors
investigated in hope of finding any relevant relationship between the two. Demographic data including age, body mass index (BMI), parity, race, menopausal status, smoking, contraceptive methods, stage, presenting symptoms and histological finding were also investigated.

**Materials and Methods**

**Institutional approval and informed consent**

This study was a descriptive study in Prapokklao Hospital, Chantaburi, Thailand. Ethical approval was approved by the Prapokklao Hospital Institutional Review Board No CTIREC 056/59. Informed consent did not require base on agreement of the Prapokklao Hospital Institutional Review Board.

**Patient populations**

This study was recruitment of all the medical record of EOC cases between January 2011 and December 2016. The inclusion criteria was all newly diagnosed EOC patients confirmed by gynecologic oncologist. Exclusion criteria were recurrent EOC and cases of non-histological proven endometriosis. All of EOC-E cases were re-confirmed by pathologist.

**Data collection**

Medical records of EOC patients were reviewed. The subjects were divided into two groups, EOC-E and EOC-NE. Data collection were baseline demographics data such as age at the time of diagnosis, body weight, height, BMI, parity, race, marital status, contraceptive methods, stage that determined according to International Federation of Gynecology and Obstetrics (FIGO) (Zeppernick et al., 2014), ultrasound finding, risk of malignancy index (RMI) (Jacob et al., 1990), clinical presentations and histological assignment based on the world health organization (WHO) Classification 2014 of OC (Meinhold-Heerlein et al., 2016). Data between two groups were compared.

Computerized commercial statistical program in this study was Stata12 (Stata Corp LLC, Texas, USA). Continuous data was represented in the form of mean and standard deviation. Categorical data was calculated with Fisher’s exact or Chi-square test. The p-value less than 0.05 was classified as statistical significance.

**Results**

**Patient’s characteristics**

During the five years of study period, 172 cases of EOC that had been diagnosed and treated by surgery and chemotherapy were recruited. According to the pathological criteria 31 (18%) patients were identified as EOC-E and 141 (82%) patients as EOC-NE (Table 1). The prevalence of endometriosis in EOC cases was 18% (31/172).

Mean age at diagnosis was 51.4 and 52.4 years old for EOC-E and EOC-NE, respectively. The demographic data are presented in Table 1.

Two-third of ultrasound finding in all EOC cases was of mixed solid cystic pattern. Mean serum level of CA-125 in EOC-E and EOC-NE were not significant difference at 1,152.3 and 1,836.7 IU/ml respectively. Seventy seven and eighty two percent of EOC-E and EOC-NE cases had RMI more than 200 respectively (Table1) that was not significant difference.

**Table 1. Demographic Characteristic of Women between EOC-E and EOC-NE**

| Characteristic | EOC-E (n=31)* | EOC-NE (n=141)* | p-value |
|----------------|--------------|-----------------|---------|
| Age**          | 51.4 (±10.1) | 52.4 (±11.9)    | 0.684   |
| <50            | 13 (41.9)    | 51 (36.2)       | 0.546   |
| ≥50            | 18 (58.1)    | 90 (63.8)       |         |
| Ethics         |              |                 |         |
| Thai           | 30 (96.8)    | 135 (95.7)      |         |
| Non-Thai       | 1 (3.2)      | 6 (4.3)         |         |
| Status         |              |                 | 0.08    |
| Single         | 13 (41.9)    | 36 (25.5)       |         |
| Marriage       | 18 (58.1)    | 105 (74.5)      |         |
| Parity         |              |                 | 0.061   |
| Nulliparity    | 16 (51.6)    | 45 (31.9)       |         |
| Primi-multiparity | 15 (48.4)   | 96 (68.1)       |         |
| BMI            |              |                 | 0.679   |
| Obesity*       | 11 (35.5)    | 45 (31.9)       |         |
| Non-obesity++  | 20 (64.5)    | 96 (68.1)       |         |
| Smoking        | 3 (9.7)      | 2 (1.4)         | 0.041   |
| Contraception  |              |                 | 0.418   |
| Hormonal       | 28 (90.3)    | 117 (83.0)      |         |
| Non-hormonal   | 3 (9.7)      | 24 (17.0)       |         |
| Underlying disease† | 0.141 |                     |         |
| Yes            | 14 (45.2)    | 43 (30.5)       |         |
| No             | 17 (54.8)    | 98 (69.5)       |         |
| Family history of cancer | 0.222 |                     |         |
| Pre            | 11 (35.5)    | 42 (29.8)       |         |
| Post           | 20 (64.5)    | 99 (70.2)       |         |
| Ultrasound finding** |         |                     |         |
| Mixed solid cystic | 19 (61.3) | 98 (69.5)       | 0.399   |
| CA125**        | 1152.3 (±2443.5) | 1838.7 (±5827.8) | 0.52    |
| <35            | 14 (12.0)    | 17 (8.0)        | 0.009   |
| ≥35            |              |                 |         |
| RMI >200       | 24 (77.4)    | 115 (81.6)      | 0.617   |
| FIGO stage     |              |                 | 0.596   |
| I              | 12 (38.7)    | 37 (26.2)       |         |
| II             | 2 (6.5)      | 10 (7.1)        |         |
| III            | 6 (19.4)     | 37 (26.2)       |         |
| IV             | 11 (35.5)    | 57 (40.4)       |         |
| Early-stage disease | 0.221 |                     |         |
| FIGO stage I-II| 14 (45.2)    | 47 (33.3)       |         |
| Advance-stage disease |         |                     |         |
| FIGO stage III-IV | 17 (54.8) | 94 (66.7)       |         |

*, n (%); **, mean ± standard deviation (SD); EOC-E, epithelial ovarian cancer coexisting with endometriosis; EOC-NE, epithelial ovarian cancer coexisting without endometriosis; + obesity, BMI (body mass index) ≥23; ++ non–obesity, BMI<22.9; † underlying disease, diabetes mellitus, hypertension, thyroid disease, autoimmune disease and hematological disease; RMI, risk of malignancy index
Prevalence and Risk Factors for Epithelial Ovarian Cancer Coexisting with Endometriosis

Histological subtype of EOC-E revealed endometroid and serous adenocarcinoma at 25.8 and 22.6%. The histological subtypes of EOC-NE were presented as serous, undifferentiated, mucinous, endometrioid, clear cell and mixed EOC at 31.2, 22.0, 19.9, 17.0, 7.1 and 2.8%, respectively.

Clear cell histological type in EOC-E was significantly found at 8 times higher incidence compared to the same type found in EOC-NE group at p-value <0.001. EOC-NE group had more incidence of undifferentiated cell type than EOC-E group at 22.0 and 6.5% respectively (Table 3).

Nulliparity is present in Table 4. It was twice more likely to be associated with EOC-E when compared to multiparity (OR 2.3, 95%CI 1.03-5.00, p-value 0.041). Smoking women had seven times higher risk of EOC-E (OR 7.4, 95%CI 1.18-46.63, p-value 0.032). Clear cell type of EOC has eight times higher association with EOC-E than EOC-NE (OR 8.0, 95% CI 2.97-21.89, p-value <0.001).

Discussion

The number of EOC cases found at Prapokklao Hospital increases annually. Multiple risk factors are correlated with EOC. Etiology of ovarian cancer is associated with

Table 2. Presenting Symptoms in EOC-E and EOC-NE

| Presenting symptom | EOC-E (n=31)* | EOC-NE (n=141)* | p-value |
|--------------------|---------------|-----------------|---------|
| Pelvic mass        | 18 (58.1)     | 66 (46.8)       | 0.32    |
| Pelvic pain        | 3 (9.7)       | 10 (7.1)        | 0.7     |
| GI*                | 4 (12.9)      | 38 (26.9)       | 0.11    |
| GU**               | 0             | 0               |         |
| AUB†               | 4 (12.9)      | 5 (3.6)         | 0.049   |
| Ascites            | 1 (3.3)       | 7 (4.9)         | 1       |
| Weight loss        | 0             | 1 (0.7)         | 1       |
| Pleural effusion   | 0             | 2 (1.4)         | 1       |
| Bowel obstruction  | 0             | 0               |         |
| Mixed symptoms     | 0             | 13              | 0.12    |

* n (%); EOC-E, epithelial ovarian cancer coexisting with endometriosis; EOC-NE, epithelial ovarian cancer coexisting without endometriosis; GI, gastrointestinal symptom; ** GU, genitourinary symptom; † AUB, abnormal uterine bleeding

FIGO staging classifications (Zeppernick et al., 2014) of EOC-E group were 12 (38.7%), 2 (6.5%), 6 (19.4%), 11 (35.5%) in the stage I, II, III, IV; respectively. FIGO staging classifications was showed in Table 1. EOC-E group mostly in the advance stage of disease (FIGO stage III-IV) that was not significant difference.

Clinical characteristics

The presenting symptoms of two study groups are shown in Table 2. Nearly half of the EOC cases were presented with abdominal mass. The percentage of abnormal uterine bleeding (AUB) in EOC-E group was significantly higher than EOC-NE group (12.9 and 3.6%, respectively, p-value 0.049). The other presenting symptoms such as gastrointestinal, genitourinary, ascites, weight loss, pleural effusion and bowel obstruction showed no significant difference between two groups (Table 2).

The comparison between histology of EOC-E and EOC-NE is present in Table 3. EOC-E showed the highest percent of cases in clear cell type [11 (35.5%)] while EOC-NE group showed 44 cases (31.2%) in serous type.

Table 3. The Comparison between Histology of EOC-E and EOC-NE

| Histology | EOC-E (n=31)* | EOC-NE (n=141)* | p-value |
|-----------|---------------|-----------------|---------|
| Serous    | 7 (22.6)      | 44 (31.2)       | 0.39    |
| Endometriod | 8 (25.8)   | 24 (17.0)       | 0.3     |
| Mucinous  | 2 (6.5)       | 28 (19.9)       | 0.11    |
| Clear cell| 11 (35.5)     | 9 (7.1)         | <0.001**|
| Brenner   | 0             | 0               |         |
| Mixed EOC | 1 (3.2)       | 4 (2.84)        | 1       |
| Undifferentiated | 2 (6.5) | 31 (22.0) | 0.040** |

*, n (%); EOC-E, epithelial ovarian cancer coexisting with endometriosis; EOC-NE, epithelial ovarian cancer coexisting without endometriosis; **, p-value<0.05.

Histological subtype of EOC-E revealed endometriod and serous adenocarcinoma at 25.8 and 22.6%. The histological subtypes of EOC-NE were presented as serous, undifferentiated, mucinous, endometriod, clear cell and mixed EOC at 31.2, 22.0, 19.9, 17.0, 7.1 and 2.8%, respectively.

Clear cell histological type in EOC-E was significantly found at 8 times higher incidence compared to the same type found in EOC-NE group at p-value <0.001. EOC-NE group had more incidence of undifferentiated cell type than EOC-E group at 22.0 and 6.5% respectively (Table 3).

Nulliparity is present in Table 4. It was twice more likely to be associated with EOC-E when compared to multiparity (OR 2.3, 95%CI 1.03-5.00, p-value 0.041). Smoking women had seven times higher risk of EOC-E (OR 7.4, 95%CI 1.18-46.63, p-value 0.032). Clear cell type of EOC has eight times higher association with EOC-E than EOC-NE (OR 8.0, 95% CI 2.97-21.89, p-value <0.001).

Table 4. Univariate and Multivariate Logistic Regression to Determine Factor Associated with Endometriosis

| Characteristic | Univariate analysis | Multivariate analysis |
|---------------|---------------------|-----------------------|
|               | Odd ratio | 95%CI | p-value | Odd ratio | 95%CI | p-value |
| Parity        |           |      |        |           |      |        |
| Nulliparity   | 2.3       | 1.03-5.00 | 0.041* | 2.1       | 0.85-4.98 | 0.105 |
| Smoking       | 7.4       | 1.18-46.63 | 0.032* | 11.3      | 1.61-79.89 | 0.015* |
| Histology     |           |      |        |           |      |        |
| Clear cell    | 8         | 2.97-21.89 | <0.001* | 9.32      | 3.26-26.67 | <0.001* |
| Endometriod   | 1.8       | 0.74-4.74 | 0.18    |           |      |        |
| Serous        | 0.6       | 0.26-1.65 | 0.382   |           |      |        |
| Infertile     | 2.5       | 0.69-8.76 | 0.164   |           |      |        |
| Suboptimal surgery | 0.4 | 0.20-1.00 | 0.052* | 0.5       | 0.19-1.16 | 0.106 |
| RMI>200       | 0.7       | 0.30-1.99 | 0.597   |           |      |        |
| OCP           | 1         | 0.28-3.95 | 0.937   |           |      |        |

EOC-E, epithelial ovarian cancer coexisting with endometriosis; *p-value<0.05
low parity, early menarche, late menopause and infertility (Berek et al., 2012). The incidence of endometriosis in general population was approximately 10% (Dinkelspiel et al., 2016) especially in women at reproductive age (Krawczyk et al., 2016). However, endometriosis had increased risk of EOC in many study (Verit et al., 2013).

Endometrioid and clear cell OC share a similar, unique pattern of associations with increased risks among women with endometriosis and decreased risks associated with tubal ligation (Berek et al., 2012).

The prevalence of epithelial ovarian cancer coexisting with endometriosis in this study was 18%. Our finding was higher than 3.4% reported eleven years ago from northern Thailand (Surprasert et al., 2006). The incidence of EOC-E reported in Asia and Europe was 14.5% and 4.2-11.3% (Surprasert et al., 2006; Jimbo et al., 1997; Scully et al., 1966; Sainz et al., 1996)

Half of patients in EOC-E group with nulliparity reported twice more risk for EOC-E. The finding agrees with previous (Berek et al., 2012). The significant differences between EOC-E and EOC-NE in this investigation showed in history of smoking that the mechanical correlation still unknown. Wentzensen reported similar association between smoking and EOC especially for mucinous epithelial ovarian cancer (Wentzensen et al., 2016).

In this study, result has a higher percentage of EOC from endometriosis cases than Thai data from ten years ago (Surprasert et al., 2006). However, our number is compatible to recent reports worldwide. Mean age of EOC-E in our study was 51.4 years old and was no significant difference from that of women in EOC-NE group. In our population, 64.5% EOC-E patients was in post-menopausal compared to 35.5% premenopausal group. In EOC-NE 70.2% patients was in postmenopausal compared to 29.8% premenopausal patients of the same condition. Our data showed that epithelial ovarian cancer with endometriosis was not associated with hormonal status both in EOC-E and EOC-NE groups.

The role of the nuclear and cytokine receptor families in ovarian cancer has been well established. Estrogen has been implicated in the progression of ovarian cancer, where estrogen transduces pro-metastatic pathways via the nuclear estrogen receptor (ER). Recent epidemiological studies have demonstrated an elevation of ovarian cancer incidence with the postmenopausal use of estrogen (Rodriguez et al., 2001; Hein et al., 2013). Our study has higher percentage of EOC cases in postmenopausal subjects. Their age of menarche, contraceptive history, lactation history, and postmenopausal management should be investigated to see if they have any correlation to OC prevalence.

Endometriosis is a disease that hormonal dependent and mostly found in premenopausal status. In this study it was found consistently in both study groups that age was not factor contributing to EOC-E and EOC-NE. Premenopausal and postmenopausal status were not a factor to define endometriosis because of in both group shown no statistical different. This finding may be explained by the work of Haidarali in year 2016 that EOC-E associated with reduction of estrogen receptor (ER) expression (Haidarali et al., 2016). While Thomsen and co-worker reported in year 2017 that hyperestrogenism (endogenous or exogenous) and/or cysts with solid compartments may have an elevated risk of epithelial ovarian cancer (Thomsen et al., 2017).

In our opinion, based on our data endometriosis can be a coincidence with EOC but not a causative of malignant transformation. This finding supported the previous data that malignant transformation from endometriosis was rare occurrence (Taniguch, 2017).

Thomas reported association between endometriosis and an increased risk of gynecologic malignancy (Thomas et al., 2012). Endometrioid and clear cell subtype of ovarian cancer were associated with endometriosis in work done by Heidemann and coworker (Heidemann et al., 2014). EOC-E in western countries was commonly presented with clear cell EOC and endometrioid EOC (8-49 and 9-39%) (Kurman et al., 1972; Russell et al., 1979). This is similar to that reported in Tokyo, Japan (Jimbo et al., 1997) and Chiangmai, Thailand (Surprasert et al., 2006). Our data supported the mentioned finding; common prevalence of histological subtype in EOC-E was clear cell type followed by endometrioid type and then serous type that demonstrated in (11/31) 35.4%, (8/31) 25.8% and (7/31) 22.5% respectively.

The histological pathology of EOC was classified by WHO Classification of Ovarian Cancer (Meinhold-Heerlein et al., 2016). One third of EOC cases were serous type (51/172) that was similar to that of the general population in the other countries. Based on the data from histological subtype, clear cell type was the most commonly found in EOC-E than in EOC-NE whereas undifferentiated cell type was more common in EOC-NE with statistical significant.

Limitations of this study may be from the small number of populations and prognostic outcome could not be identified because of retrospective study. From the new WHO Classification of Ovarian Cancer published 2014 (Meinhold-Heerlein et al., 2016), the histological confirm in subtype of serous adenocarcinoma (Kurman and Shih, 2010) can’t be evaluation due to lack of pathological review with immunohistochemistry.

In conclusion, prevalence of EOC-E in our institute was 18 %. Clear cell adenocarcinoma was mostly found in EOC-E. Baseline clinical characteristic was difficult to use as the screening methods for detection of abnormal and high risk patients on EOC. Abnormal uterine bleeding was statistical significant of EOC-E. Endometriosis was mostly found in one quarter of serous carcinoma. Endometriosis coexisting with epithelial ovarian cancer in this study was not correlated with younger age or menopausal status. However, continuous treatment of endometriosis should be in highly precaution especially in postmenopausal women.

Funding Statement
None.

Statement conflict of Interest
The authors declare no conflict of interest.
Acknowledgements

We would like to thank Yosaporn Leuangsomnapa for provide insight and expertise that greatly assist the research.

References

Berek JS, Longacre TA, Friedlander M (2012). Ovarian, Follapian tube and peritoneal cancer. In Berek and Novak’s gynecology 15th ed, Eds Berek JS, Lippincott Williams and Willkins. Philadelphia, pp 1350-427.

Bousson VE, Ferrero A, Fusco L, et al (2016). Endometriosis-associated ovarian cancer: a distinct clinical entity. Anti Cancer Res, 36, 3445-9.

Del Carmen MG (2015). Evidence for the relationship between endometriosis and epithelial ovarian cancer. Obstet Gynecol Surv, 70, 587-95.

Dinkelspiel HE, Matrai C, Pauk S, et al (2016). Does the presence of endometriosis affect prognosis of ovarian cancer?. Cancer Invest, 34, 148-54.

Haidarali E, Vahedi A, Mohajeri Sh, et al (2016). Evaluation of the pathogenesis of tumor development from endometriosis by estrogen receptor, P53 and Bel-2 immunohistochemical staining. Asian Pac J Cancer Prev, 17, 5247-50.

Heidemann LN, Hartwell D, Heidemann CH, Jochumsem KM (2014). The relation between endometriosis and ovarian cancer a review. Acta Obstet Gynecol Scand, 93, 20–31.

Hein A, Thiel FC, Bayer CM, Fasching PA, Haberle L, et al (2013). Hormone replacement therapy and prognosis in ovarian cancer patients. Eur J Cancer Prev, 22, 52-8.

Imasamran W, Chaiwarawattana A, Wiangnon S, et al (2015). Cancer in Thailand 2010-2012, New Thammada Press, Bangkok, VIII, pp 55-8.

Jacobs I, Oram D, Fairbanks J, et al (1990). A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol, 97, 922-9.

Jimbo H, Yoshikawa H, Onda T, et al (1997). Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynecol Obstet, 59, 245-50.

Kurman RJ, Shih IeM (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol, 34, 433-43.

Kurman RJ, Shih IeM (2008). Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol, 27, 151-60.

Krawczyk N, Banys-Paluchowski M, Schmidt D, Ulrich U, Fehm T (2016). Endometriosis - associated malignancy. Geburtshilfe Frauenheilk, 76, 176–81.

Kurman RJ, Craig JM (1972). Endometrioid and clear cell carcinoma of the ovary. Cancer, 29, 1653-64.

Meinhold-Heerlein I, Fotopoulou C, Harter P, et al (2016). The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet, 293, 695-700.

Munksgaard PS, Blaakaer J (2011). The association between endometriosis and ovarian cancer: A review of histological, genetic and molecular alterations. Gynecol Oncol, 124, 164-9.

Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001). Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA, 285, 1460-5.

Russell P (1979). The pathological assessment of ovarian neoplasms: Introduction to the common epithelial tumors and analysis of benign epithelial tumors. Pathology, 11, 5-26.

Sainz de la Cuesta R, Eichhorn JH, et al (1996). Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol, 60, 238-44.

Scully RE, Richardson GS, Barlow JF (1966). The development of malignancy in endometriosis. Clin Obstet Gynecol, 9, 384-411.

Surprasert P, Khunamornpong S, Srisomboon J (2006). Clinicopathological features and prognosis of Thai women with endometriosis associated ovarian carcinoma. Asian Pac J Cancer Prev, 7, 638-40.

Taniguchi F (2017). New knowledge and insights about the malignant transformation of endometriosis. J Obstet Gynaecol Res, 43, 1093-100.

Thomas M, D’Hooghe.Jonathan S. Berek, et al (2012). Endometriosis, In Berek and Novak’s gynecology 15th ed, Eds Berek JS. Lippincott Williams and Willkins. Philadelphia, pp 505-56.

Thomsen LH, Schnack TH, Buchardi K, et al (2017). Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand, 96, 761-78.

Verit FF, Yucel O (2013). Endometriosis, leiomyoma and adenomyosis: the risk of gynecologic malignancy. Asian Pac J Cancer Prev, 14, 5589-97.

Wentzensen N, Poole EM, Trabert B, et al (2016). Ovarian cancer risk factors by histologic subtype: An analysis from the ovarian cancer cohort consortium. J Clin Oncol, 34, 888-98.

Zeppernick F, Meinhold-Heerlein I (2014). The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet, 290, 839-42.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.